Advanced Enzyme Technologies Ltd.

₹317.6

4.2 (1.3%)

ADVENZYMES Share Price

Pharmaceuticals & Biotechnology

As on July 3, 2026

SectorHealthcare

IndustryPharmaceuticals & Biotechnology

Basic IndustryBiotechnology

Market Cap₹ 3,594 Cr

P/E Ratio27.1

Dividend Yield0.82 %

Trendline Performance

We are partnered with TradingView, a global leader in charting and market analysis. Access real-time stock data, explore the powerful Stock Screener , and uncover insights with multiple tools designed for traders.

Unlock Stock of the Month

T&C*

Technicals

Indicators	Value	Signal
5-DMA	314.85	Bullish
10-DMA	341.47	Bearish
20-DMA	355.49	Bearish
50-DMA	358.48	Bearish
100-DMA	324.75	Bearish
200-DMA	317.29	Bullish

Historical Performance

1 Year

-6%

3 Years

12.3%

5 Years

-22.1%

10 Years

N/A

Shareholding Pattern

Values Analysis

Loading chart...

Profit & Loss

Below figures are in Rs. Crores

Particulars	Mar-2025	Mar-2024	Mar-2023	Mar-2022	Mar-2021
Net Sales	6,369	6,239	5,406	5,294	5,018
Total Expenditure	4,414	4,185	3,831	3,268	2,693
Other Income	330	370	255	64	88
Operating Profit	2,286	2,423	1,830	2,090	2,414
Interest	46	41	35	30	26
Depreciation	366	352	350	350	287
Profit Before Tax	1,874	1,878	1,404	1,711	2,101
Consolidated Net Profit	1,311	1,333	1,056	1,196	1,459
Adjusted EPS	12	12	9	11	13

Compounded Sales Growth

10 Years:23.3

5 Years:7.5

3 Years:3.8

TTM:0.4

Compounded Profit Growth

10 Years:20.8

5 Years:0.3

3 Years:1.9

TTM:-0.3

Stock Price CAGR

10 Years:N/A

5 Years:-4.9

3 Years:3

TTM:-6.1

Return on Equity

10 Years:7

5 Years:13.1

3 Years:9.4

last year:11.7

Quarterly Results

Below figures are in Rs. Crores

Particulars	Sep-2024	Dec-2024	Mar-2025	Jul-2025	Sep-2025
Sales	1,70,754	1,35,936	1,28,552	1,22,189	1,05,161
Expenses	63,042	56,557	52,457	45,459	34,856
Operating Profit	1,07,712	79,379	76,096	76,730	70,304
OPM %	63%	58%	59%	63%	67%
Other Income	33,912	31,759	27,333	24,879	18,947
Interest	77,780	58,584	59,248	62,137	53,713
Depreciation	2,345	1,681	1,385	1,277	1,221
Profit Before Tax	61,498	50,873	42,796	38,195	34,318
Tax %	25%	25%	26%	29%	35%
Net Profit	46,149	38,151	31,857	27,296	22,446
EPS in Rs	83	69	58	50	42

Balance Sheet

Below figures are in Rs. Crores

Particulars	Mar-2025	Mar-2024	Mar-2023	Mar-2022	Mar-2021
Share Capital	224	224	224	224	223
Total Reserves	13,935	12,987	12,127	10,656	9,460
Long-Term Borrowings	---	---	---	---	---
Total Non-Current Liabilities	457	437	488	594	491
Other Current Liabilities	424	442	432	366	434
Short Term Borrowings	111	176	50	19	47
Total Liabilities	16,112	15,212	14,105	12,602	11,493
Capital Work in Progress	217	307	156	96	49
Long Term Loans & Advances	238	190	163	175	149
Currents Investments	4,803	4,028	3,596	1,019	1,213
Short Term Loans and Advances	107	241	87	120	76
Total Current Assets	8,799	8,097	7,221	6,044	5,160
Total Assets	16,112	15,212	14,105	12,602	11,493
Adjusted Book Value	127	118	110	97	87

Positive

(80 to 100)

Neutral

(60 to 79)

Negative

(0 to 59)

The stock has a high PE of 27.1, indicating expensive valuation or elevated growth expectations.
Over the last three years, the stock delivered a weak 3-year price CAGR of 3.0%, indicating poor shareholder returns.
The stock carries a beta of 0.9, indicating volatility broadly in line with the market.
In the last financial year, the company reported an EBITDA of ₹2286 million, reflecting positive operating performance.
In the previous financial year, the company generated revenue of ₹6369 million, suggesting a mid-sized operation.

Investment Calculator

Investment Amount:₹

Investment Amount: ₹ 1000000

Current Value: ₹ 940340.5

No. of Shares: 2961 (Approx)

Performance:-6%

P/L: ₹-59659.5

NIFTY Performance: -4.7%

1 day Top Gainers